Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ZYRTEC HIVES versus DECABID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ZYRTEC HIVES versus DECABID.
CHILDREN'S ZYRTEC HIVES vs DECABID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cetirizine is a selective antagonist of peripheral histamine H1 receptors, inhibiting histamine-mediated allergic reactions.
Decabid is a combination of chlorpheniramine (antihistamine) and pseudoephedrine (decongestant). Chlorpheniramine competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine acts as a sympathomimetic agent, stimulating alpha-adrenergic receptors to cause vasoconstriction, reducing nasal congestion.
5 mg or 10 mg orally once daily; maximum 10 mg/day.
1 capsule orally every 12 hours; each capsule contains 10 mg phenylephrine hydrochloride and 75 mg carbinoxamine maleate.
None Documented
None Documented
Terminal elimination half-life is approximately 8-11 hours in healthy adults, allowing twice-daily dosing.
12 hours (terminal); prolonged to 24 hours in renal impairment (CrCl <30 mL/min)
Cetirizine is primarily excreted renally (~60% unchanged), with ~10% fecal excretion.
Renal (50% as unchanged drug), fecal (40% as metabolites), biliary (10% as glucuronide conjugates)
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination